U.S. Markets closed

ImmunoClin Corporation (IMCL)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1592770.000000 (0.000000%)
At close: 3:22PM EDT

ImmunoClin Corporation

1420 North Street
Suite 102
Washington, DC 20005
United States

Full Time Employees

Key Executives

Dr. Dorothy Helen Bray Ph.D.Chief Exec. Officer, Pres and Director21kN/A61
Mr. James Scott MunroChief Financial Officer and Treasurer20kN/A48
Dr. Khadija Benlhassan Ph.D.Chief Scientific Officer and Director1kN/A42
Mr. Raymond C. DabneyManagement Consultant21kN/A52
Amounts are as of December 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Immunoclin Corporation provides comprehensive, clinical, and basic science research services to pharmaceutical, biotechnology, and food industries. It is involved in the research and development on products, such as MIRA, an algorithm to analyze the multi-variant data to identify people who are at risk of having heart attack; and GARD, a genetic test for multiple genetic polymorphisms associated with increased risk of the most common form of dementia. Immunoclin Corporation is also engaged in the research and development of PRIMALEUKIN, an antibacterial, anti-fungal, and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from, infection; DACTELLIGENCE, a technology and newly patented concept in bio-sensing to challenge detection platforms in multiple diagnostic fields; and GastroWellBeing, an immunological food supplement. The company was formerly known as Pharma Investing News, Inc. and changed its name to Immunoclin Corporation in December 2013. Immunoclin Corporation is based in Washington, the District of Columbia.

Corporate Governance

ImmunoClin Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.